Spironolactone is NOT approved for psychiatric indications, but emerging research suggests potential off-label benefits for certain psychiatric conditions, particularly schizophrenia and bipolar disorder.
FDA-Approved Indications
Spironolactone has no FDA-approved psychiatric indications. The approved uses are strictly medical 1:
- Heart failure (NYHA Class III-IV)
- Hypertension
- Edema associated with hepatic cirrhosis or nephrotic syndrome
Emerging Psychiatric Applications (Off-Label)
Schizophrenia
Recent clinical trials demonstrate potential cognitive benefits in schizophrenia through antagonism of the NRG1-ERBB4 signaling pathway 2. A 2026 randomized controlled trial in 90 patients with schizophrenia tested spironolactone (100 mg or 200 mg) versus placebo for three weeks. While pre-specified analyses did not show significant superiority over placebo, post-hoc sensitivity analyses suggested significant advantages for working memory improvement, particularly at the 200 mg dose 2.
An earlier 2022 trial showed more definitive results: spironolactone 100 mg/day as adjunctive therapy to risperidone significantly improved PANSS negative, positive, and total scores compared to placebo over 8 weeks (p=0.004,0.007, and 0.042 respectively) 3. The effect sizes were substantial (Cohen's d: 0.96 for negative symptoms, 0.90 for positive symptoms).
Bipolar Disorder
Spironolactone as adjunctive therapy may improve cognitive function and stress response in bipolar disorder 4, 5. A 2023 double-blind RCT in 60 patients with bipolar-I disorder in manic episodes found significant improvement in cognitive performance (MMSE) at week 8 (B = -1.60, p = 0.021), though manic symptoms (YMRS) did not show significant improvement 4.
A 2009 case series reported improved stress response and residual symptoms in four euthymic bipolar patients treated with adjunctive spironolactone 5.
Mechanism of Action in Psychiatric Conditions
The psychiatric effects appear mediated through:
- Antagonism of NRG1-ERBB4 signaling pathway, which is critically linked to working memory dysfunction in schizophrenia 2, 6
- Mineralocorticoid receptor antagonism in the hippocampus, potentially modulating stress response and HPA axis dysfunction in affective disorders 5
Important Caveats
Safety Concerns
The standard adverse effects apply 1:
- Hyperkalemia (requires monitoring in at-risk patients)
- Menstrual irregularities (15-30% of women)
- Gynecomastia in males (dose-dependent: 7% at <50 mg/day, 52% at >150 mg/day)
- Decreased libido
- Gastrointestinal effects
Evidence Limitations
- All psychiatric applications are off-label and investigational
- Sample sizes remain small
- Treatment durations in trials were short (3-8 weeks)
- Long-term efficacy and safety data are lacking
- Results are mixed, with some trials showing only post-hoc significance
Clinical Reality
Spironolactone should not be prescribed solely for psychiatric indications outside of research protocols. The evidence base is insufficient for routine clinical use. If considered, it should only be as adjunctive therapy in treatment-resistant cases under close monitoring, with explicit informed consent about off-label use.
The primary clinical utility remains its FDA-approved cardiovascular and endocrine indications, with psychiatric benefits being an area of active investigation rather than established practice.